C WorldWide Group Holding A S Has $11.38 Million Stake in Edwards Lifesciences Corporation (EW)

C WorldWide Group Holding A S lowered its stake in Edwards Lifesciences Corporation (NYSE:EW) by 9.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 96,262 shares of the medical research company’s stock after selling 9,466 shares during the period. C WorldWide Group Holding A S’s holdings in Edwards Lifesciences Corporation were worth $11,382,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of the company. YorkBridge Wealth Partners LLC acquired a new stake in Edwards Lifesciences Corporation during the first quarter worth $110,000. NEXT Financial Group Inc boosted its stake in Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock worth $115,000 after buying an additional 500 shares in the last quarter. Shine Investment Advisory Services Inc. acquired a new stake in Edwards Lifesciences Corporation during the second quarter worth $126,000. Cornerstone Advisors Inc. boosted its stake in Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock worth $129,000 after buying an additional 219 shares in the last quarter. Finally, Alexandria Capital LLC boosted its stake in Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock worth $136,000 after buying an additional 19 shares in the last quarter. Institutional investors and hedge funds own 84.15% of the company’s stock.

Edwards Lifesciences Corporation (NYSE EW) opened at 114.13 on Friday. The company has a market capitalization of $24.10 billion, a price-to-earnings ratio of 34.62 and a beta of 0.63. Edwards Lifesciences Corporation has a 12-month low of $81.12 and a 12-month high of $121.75. The firm’s 50-day moving average price is $117.06 and its 200 day moving average price is $105.21.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The firm had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. During the same period last year, the business posted $0.76 EPS. The business’s revenue was up 10.9% compared to the same quarter last year. On average, analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “C WorldWide Group Holding A S Has $11.38 Million Stake in Edwards Lifesciences Corporation (EW)” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.com-unik.info/2017/08/11/c-worldwide-group-holding-a-s-has-11-38-million-stake-in-edwards-lifesciences-corporation-ew.html.

A number of research firms recently weighed in on EW. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 price target (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Cowen and Company reissued an “outperform” rating and issued a $135.00 target price (up from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Zacks Investment Research cut Edwards Lifesciences Corporation from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 13th. Finally, Jefferies Group LLC lifted their target price on Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $121.13.

In other Edwards Lifesciences Corporation news, VP Catherine M. Szyman sold 4,681 shares of the stock in a transaction dated Monday, July 31st. The stock was sold at an average price of $115.78, for a total transaction of $541,966.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Patrick B. Verguet sold 22,631 shares of the stock in a transaction dated Friday, May 19th. The stock was sold at an average price of $113.16, for a total value of $2,560,923.96. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 183,412 shares of company stock valued at $21,176,230. Company insiders own 2.13% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit